Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021

International Journal of Environmental Research and Public Health

Daniel Lindsay¹  Richard Johns²  Rachel E. Neale³  David C. Whiteman³  Louisa G. Gordon³  Catherine M. Olsen³  Thomas M. Elliott³  Nirmala Pandeya³  Katharina M. D. Merollini⁴  Bronwen McNoe⁵  William Leung⁶ 

[1] Faculty of Medicine, The University of Queensland, Brisbane, QLD 4006, Australia;Kenmore Skin Clinic, Moggill Rd, Brisbane, QLD 4069, Australia;Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia;School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore, QLD 4558, Australia;Social and Behavioural Research Unit, Department of Preventive and Social Medicine, University of Otago, Dunedin 9016, New Zealand;Wellington School of Medicine, University of Otago, Wellington 6242, New Zealand;

关键词: melanoma;    keratinocyte cancer;    basal cell carcinoma;    squamous cell carcinoma;    cost-of-illness;    Markov model;   

DOI  :  10.3390/ijerph19063178

来源: DOAJ

【 摘 要 】

Australia and Aotearoa New Zealand have the highest incidence of melanoma and KC in the world. We undertook a cost-of-illness analysis using Markov decision–analytic models separately for melanoma and keratinocyte skin cancer (KC) for each country. Using clinical pathways, the probabilities and unit costs of each health service and medicine for skin cancer management were applied. We estimated mean costs and 95% uncertainty intervals (95% UI) using Monte Carlo simulation. In Australia, the mean first-year costs of melanoma per patient ranged from AU$644 (95%UI: $642, $647) for melanoma in situ to AU$100,725 (95%UI: $84,288, $119,070) for unresectable stage III/IV disease. Australian-wide direct costs to the Government for newly diagnosed patients with melanoma were AU$397.9 m and AU$426.2 m for KCs, a total of AU$824.0 m. The mean costs per patient for melanoma ranged from NZ$1450 (95%UI: $1445, $1456) for melanoma in situ to NZ$77,828 (95%UI $62,525, $94,718) for unresectable stage III/IV disease. The estimated total cost to New Zealand in 2021 for new patients with melanoma was NZ$51.2 m, and for KCs, was NZ$129.4 m, with a total combined cost of NZ$180.5 m. These up-to-date national healthcare costs of melanoma and KC in Australia and New Zealand accentuate the savings potential of successful prevention strategies for skin cancer.

【 授权许可】

Unknown